"Frutto dell’alleanza tra soggetti pubblici e appartenenti al privato sociale, l’Istituto Scientifico Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST è riferimento nazionale in campo oncologico. La sua missione consiste nel promuovere e realizzare attività di cura, studio e ricerca, in particolare ricerca traslazionale. Operativo dal 2007 all’interno delle strutture dell'ex Ospedale Civile di Meldola (Forlì-Cesena) ha sedi a Forlì, Cesena e Ravenna (Radioterapia) ed è riconosciuto quale Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS)."

During the past decade, UO Oncologia Medica IRCCS IRST conducted 10 clinical trials. In the 10-year time frame, 10 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

In terms of collaborators to trials, out of the total clinical trials conducted in "UO Oncologia Medica IRCCS IRST" #1 collaborator was "Agenzia Italiana del Farmaco" with 1 trials as a collaborator and "ERIC Group" with 1 trials as a collaborator. Other collaborators include -2 different institutions and companies that were collaborators in the rest 2 trials.

According to Clinical.Site data, the most researched conditions in "UO Oncologia Medica IRCCS IRST" are "AML, Adult" (1 trials), "Acute Lymphoid Leukemia" (1 trials), "Adjuvant Drug Therapy" (1 trials), "Chronic Lymphocytic Leukemia" (1 trials) and "Chronic Myeloid Leukemia" (1 trials). Many other conditions were trialed in "UO Oncologia Medica IRCCS IRST" in a lesser frequency.

Most popular intervention types in "UO Oncologia Medica IRCCS IRST" are "Drug" (12 trials), "Other" (2 trials), "Biological" (1 trials), "Genetic" (1 trials) and "Procedure" (1 trials). Other intervention types were less common.

The name of intervention was led by "Arm A : Gemcitabine + Pemetrexed" (1 trials), "Autologous Dendritic Cell vaccine" (1 trials), "Boost of radiotherapy + high dose IL-2 treatment" (1 trials), "DOX 2 cycles - Surgery - DOX 2 cycles" (1 trials) and "DOX 4 cycles - Surgery" (1 trials). Other intervention names were less common.

The vast majority of trials in "UO Oncologia Medica IRCCS IRST" are 13 trials for "All" genders, 2 trials for "Female" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "UO Oncologia Medica IRCCS IRST". undefined are not yet recruiting, 1 are recruiting, 2 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 5 completed trials in UO Oncologia Medica IRCCS IRST, undefined suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in UO Oncologia Medica IRCCS IRST, 1 "Phase 1" clinical trials were conducted, 12 "Phase 2" clinical trials and 0 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 0 trials that are defined as “Not Applicable".